NCT06039137View on ClinicalTrials.gov

The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

CompletedOBSERVATIONAL
Enrollment

395

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

April 27, 2023

Study Completion Date

October 31, 2023

Conditions
Solid Tumor
Interventions
DRUG

Cetirizine

Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine

DRUG

Clemastine IV

Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV

Trial Locations (1)

3015 GD

Erasmus University Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER